Studie zu Serin und Fenofibrat bei Patienten mit MacTel Typ 2 (SAFE)
Phase-2a-Studie zur Wirkung einer Serin-Supplementierung und einer Behandlung mit Fenofibrat auf die Serum-Deoxysphinganin-Spiegel bei Patienten mit makulärer Teleangiektasie (MacTel) Typ 2 (SAFE-Studie)
This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms. Participants will be randomly assigned to one of the following treatment groups: serine 200 mg/kg/day, serine 400 mg/kg/day, fenofibrate 160 mg/day, both serine 200 mg/kg/day and fenofibrate 160 mg/day, both serine 400 mg/kg/day and fenofibrate 160 mg/day, or no treatment (control group). Serum deoxysphingolipid levels will be used as the primary outcome, and safety will be evaluated. The participants will be followed for 10 weeks, with visits at Screening, Week 0, 3, 6 and 10.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Additional Procedures include:
- Fasting blood work
- Collection of microbiome samples
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Emory University
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48105
- Kellogg Eye Center, University of Michigan
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44122
- Retina Associates of Cleveland
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37922
- Southeastern Retina Associates
-
-
Texas
-
Bellaire, Texas, Vereinigte Staaten, 77401
- Retina Consultants of Texas
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84132
- Moran Eye Center, University of Utah
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- University of Washington
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- The Eye Institute, Medical College of Wisconsin
-
-
-
-
-
London, Vereinigtes Königreich, ECV2PD
- Moorfields Eye Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Signed and dated written informed consent obtained from the participant in accordance with the local regulations;
- Males/females 21 years of age or older;
- English speaking;
- Enrolled in the Natural History Observation and Registry Study (NHOR) and diagnosed with confirmed MacTel type 2 in at least one eye;
- Willing to use contraception, if applicable; and
- Willing to comply with study protocol and follow-up visits.
Exclusion Criteria:
- Participant is unable to provide informed consent;
- Participant is less than 21 years of age;
- Participant is currently taking, or has taken within four weeks prior to screening, a serine or glycine supplement;
- Participant is currently taking, or has taken within 12 months prior to screening, fibrates including clofibrate, ciprofibrate, bezafibrate, fenofibrate, and gemfibrozil;
- Participant is currently taking an anticoagulant, colchicine, cyclosporine, tacrolimus or bile acid binding resins;
- Participant has known allergy to fibrates and/or serine;
- Participant has a known history of clinically significant myopathy or myalgia related to cholesterol-lowering drugs;
- Participant has active liver disease and/or elevated liver enzymes*;
- Participant has renal dysfunction as evidenced by elevated serum creatinine* and/ or glomerular filtration rate (GFR) less than 90 mL/min;
- Participant has thrombocytopenia as evidenced by a platelet count below 100,000 per microliter, anemia as evidenced by hemoglobin levels below 10 g/dL, or history of bleeding disorder;
- Participant has a history of gallbladder disease or has had a cholecystectomy;
- Participant has triglyceride levels greater than 400 mg/dL on treatment, or greater than 700 mg/dL on no treatment;
- Participant has untreated/uncured Hepatitis C, or a history of Hepatitis B, autoimmune hepatitis, or HIV;
- Participant has had any malignancies within the last 5 years (not including basal cell carcinoma);
- Participant has ever been enrolled in a clinical trial involving ciliary neurotrophic factor (CNTF) treatment;
- Participant is currently enrolled in another clinical trial that involves treatment or participated in one within the last 30 days;
- Participant is pregnant, breastfeeding or planning a pregnancy;
- Participant is medically unable to comply with study procedures or follow-up visits;
- Participant has, in the opinion of the Investigator, any physical or mental condition that would increase the patient's risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments; or
- Patient is unavailable for follow-up visits. *based on reference range for the local laboratory used
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Fakultätszuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Serine 200 mg/kg/day
Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)). |
Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally) |
|
Experimental: Serine 400 mg/kg/day
Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)). |
Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally) |
|
Experimental: Fenofibrate 160 mg/day
Fenofibrate 160 mg per day. To be taken once per day for 6 weeks. |
Fenofibrate 160mg pill, taken orally |
|
Experimental: Serine 200 mg/kg/day and Fenofibrate 160 mg/day
Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)). Fenofibrate 160 mg per day. To be taken once per day for 6 weeks. |
Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally) Fenofibrate 160mg pill, taken orally |
|
Experimental: Serine 400 mg/kg/day and Fenofibrate 160 mg/day
Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)). Fenofibrate 160 mg per day. To be taken once per day for 6 weeks. |
Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally) Fenofibrate 160mg pill, taken orally |
|
Kein Eingriff: No treatment
Control group: no investigational product taken |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety Assessment
Zeitfenster: Reported over the10 weeks from baseline to exit visit
|
Safety assessment measured via examined AEs and SAEs (during study visits) and via participant self-reported AEs and SAEs that occurred between visits |
Reported over the10 weeks from baseline to exit visit
|
|
Percentage Change of Serum Deoxysphingolipid Levels From Baseline to 6 Weeks
Zeitfenster: Blood draw at baseline and 6 weeks on product
|
Percentage change in the sum of 7 different deoxy-dihydroceramides species detected. Negative values mean these metabolites decreased during the treatment period. Deoxy-sphingolipids were measured in serum using LC-MS. |
Blood draw at baseline and 6 weeks on product
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage Change in Serum Lipid Levels From Baseline to 6 Weeks
Zeitfenster: blood draws from baseline and week 6 on product
|
Percent changes in lipid levels measured between baseline and 6 weeks. These lipid levels were obtained from the local clinical lab at each site as part of a lipid panel. Negative values mean these metabolites decreased during the treatment period. |
blood draws from baseline and week 6 on product
|
|
Percentage Change in Serum Serine and Glycine Levels From Baseline to 6 Weeks
Zeitfenster: blood draws from baseline and week 6 on product
|
Percentage change in fasting levels of the two amino acids serine and glycine. Serine supplementation is part of the treatment and glycine can be produced from serine by different cells in the body. Serine and glycine levels were measured from serum using LC-MS. |
blood draws from baseline and week 6 on product
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Mari A Gantner, PhD, Lowy Medical Research Institute
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Aminosäuren, Peptide und Proteine
- Organische Chemikalien
- Ethers
- Kohlenwasserstoffe
- Kohlenwasserstoffe, zyklisch
- Säuren, acyclisch
- Carboxylsäuren
- Kohlenwasserstoffe, aromatisch
- Aminosäuren
- Phenole
- Benzolderivate
- Butyate
- Phenylether
- Ketone
- Fibrikäuren
- Isobutyate
- Benzophenone
- Aminosäuren, neutral
- Fenofibrat
- Serin
Andere Studien-ID-Nummern
- 2020-002
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .